MCID: BRN120
MIFTS: 39

Bronchus Cancer

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchus Cancer

MalaCards integrated aliases for Bronchus Cancer:

Name: Bronchus Cancer 12 14
Bronchial Neoplasms 41 69
Bronchus Carcinoma 12 14
Bronchial Neoplasm 12 14
Malignant Neoplasm of Bronchus and Lung, Unspecified 12
Malignant Neoplasm of Bronchus or Lung, Unspecified 12
Malignant Neoplasm of Bronchus or Lung Nos 12
Bc - Bronchogenic Carcinoma 12
Carcinoma, Bronchogenic 41
Bronchogenic Carcinoma 69
Neoplasm of Bronchus 12
Bronchus Neoplasm 12

Classifications:



Summaries for Bronchus Cancer

Disease Ontology : 12 A bronchus cancer that has material basis in epithelial cells.

MalaCards based summary : Bronchus Cancer, also known as bronchial neoplasms, is related to main bronchus cancer and bronchus carcinoma in situ, and has symptoms including hemoptysis, fever and dyspnea. An important gene associated with Bronchus Cancer is CD6 (CD6 Molecule), and among its related pathways/superpathways is Vasopressin-regulated water reabsorption. The drugs Cisplatin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Bronchus Cancer

Diseases in the Bronchus Cancer family:

Bronchus Carcinoma in Situ

Diseases related to Bronchus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 main bronchus cancer 12.2
2 bronchus carcinoma in situ 12.0
3 lung cancer 11.0
4 bronchus mucoepidermoid carcinoma 11.0
5 pulmonary blastoma 10.3
6 pleuropulmonary blastoma type 1 10.3
7 pleuropulmonary blastoma type 2 10.3
8 pleuropulmonary blastoma type 3 10.3
9 polyradiculopathy 10.2 AVPR2 CD6
10 hyper-igd syndrome 10.1 CRP SAA1
11 amyloidosis aa 10.1 CRP SAA1
12 nephrogenic syndrome of inappropriate antidiuresis 10.0 AVP AVPR2
13 inappropriate adh syndrome 10.0 AVP AVPR2
14 dental abscess 10.0 AVP CRP
15 impaired renal function disease 10.0 AVP AVPR2
16 syndrome of inappropriate antidiuretic hormone 10.0 AVP AVPR2
17 peripheral vertigo 10.0 AVP CRP
18 familial mediterranean fever 10.0 CRP SAA1
19 finger agnosia 10.0 CD6 ENO2
20 diabetes insipidus, neurohypophyseal 10.0 AVP AVPR2
21 analbuminemia 10.0 AVP CRP
22 granulomatous hepatitis 9.9 AVP CRP
23 supraglottis cancer 9.9 CD6 ENO2
24 pancreas disease 9.9 AVP CRP
25 diabetes insipidus, nephrogenic, autosomal 9.9 AVP AVPR2
26 miliary tuberculosis 9.9 CRP ENO2
27 diabetes insipidus 9.9 AVP AVPR2
28 bronchiectasis 9.8
29 urinary system disease 9.8 AVP CRP
30 congenital epulis 9.8 AVPR2 ENO2
31 actinomycosis 9.8
32 pancoast tumor 9.8 AVP ENO2
33 olfactory nerve neoplasm 9.8 AVP ENO2
34 dysentery 9.8 CRP ENO2
35 pleurisy 9.8 CRP ENO2
36 cranial nerve malignant neoplasm 9.8 AVP ENO2
37 cervix small cell carcinoma 9.8 AVP ENO2
38 appendicitis 9.7 CRP ENO2
39 aging 9.7
40 situs inversus 9.7
41 mediastinitis 9.7
42 autosomal dominant polycystic kidney disease 9.7 AVP AVPR2
43 adenoiditis 9.7
44 esophagitis 9.7
45 conn's syndrome 9.7
46 megaesophagus 9.7
47 mucoepidermoid carcinoma 9.7
48 achalasia 9.7
49 cardiac arrest 9.6 AVP ENO2
50 small cell cancer of the lung 9.5 AVP ENO2

Graphical network of the top 20 diseases related to Bronchus Cancer:



Diseases related to Bronchus Cancer

Symptoms & Phenotypes for Bronchus Cancer

UMLS symptoms related to Bronchus Cancer:


hemoptysis, fever, dyspnea, coughing

GenomeRNAi Phenotypes related to Bronchus Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 8.92 AVPR2 SAA1
2 Decreased viability GR00381-A-3 8.92 SAA1 AVPR2

Drugs & Therapeutics for Bronchus Cancer

Drugs for Bronchus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 695)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 150399-23-8, 137281-23-3 60843 446556
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 38904 498142
6
Gefitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 184475-35-2 123631
7
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
8
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
9
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 241903 13342
10
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71486-22-1 44424639 60780
11
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
13
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
14
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
15
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 112111-43-0
16
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
17
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
18
Trametinib Approved Phase 4,Phase 1,Phase 2 871700-17-3 11707110
19
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1374853-91-4
20
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
21
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
22
Dabrafenib Approved, Investigational Phase 4,Phase 2 44462760 44516822
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
25
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
27
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124 9877265
28
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
29
Lactitol Investigational Phase 4,Phase 2,Phase 1 585-86-4 3871
30 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Endostatins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71581480
34 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 183319-69-9 176871
45 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Mitogens Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 4042)

# Name Status NCT ID Phase Drugs
1 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
2 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
3 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
4 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
5 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
6 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
7 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
8 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
9 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
10 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
11 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
12 PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) Unknown status NCT00173524 Phase 4
13 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
14 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed NCT02208843 Phase 4 Afatinib
15 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
16 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
17 Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose Completed NCT01465243 Phase 4 Icotinib
18 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
19 Iressa Case Control Study in Japan Completed NCT00252759 Phase 4
20 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
21 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4 Nolbaxol;Taxotere;cisplatin
22 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
23 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
24 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
25 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
26 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4 erlotinib [Tarceva]
27 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4 Erlotinib
28 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
29 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
30 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
31 A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
32 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4 Erlotinib
33 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
34 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4 Gefitinib;Placebo
35 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
36 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
37 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
38 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
39 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
40 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
41 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
42 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
43 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
44 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
45 Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients. Recruiting NCT03460678 Phase 4 Pemetrexed;Erlotinib
46 A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Recruiting NCT03285763 Phase 4 Atezolizumab
47 Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery Recruiting NCT03172988 Phase 4 Dexamethasone;Normal saline;Flurbiprofen axetil;Lipid microsphere
48 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Recruiting NCT02514174 Phase 4 Afatinib
49 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation Recruiting NCT02404675 Phase 4 icotinib
50 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Recruiting NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy

Search NIH Clinical Center for Bronchus Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: bronchial neoplasms

Genetic Tests for Bronchus Cancer

Anatomical Context for Bronchus Cancer

MalaCards organs/tissues related to Bronchus Cancer:

38
Lung

Publications for Bronchus Cancer

Articles related to Bronchus Cancer:

(show all 27)
# Title Authors Year
1
Dosimetric impact of an air passage on intraluminal brachytherapy for bronchus cancer. ( 27605630 )
2016
2
Incidence rates for lung and bronchus cancer of Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. ( 27380807 )
2016
3
Racial and Gender Disparities in Incidence of Lung and Bronchus Cancer in the United States: A Longitudinal Analysis. ( 27685944 )
2016
4
Stat Bite Percentage of New Caces by Age Group For Lung and Bronchus Cancer (2008-2012). ( 26944763 )
2016
5
Lung and bronchus cancer in Puerto Rico: changes in incidence and mortality rates by histology and sex during 1987-2003: comment on the article by Rivas et al. ( 22783701 )
2012
6
Lung and bronchus cancer in Puerto Rico: changes in incidence and mortality rates by histology and sex during 1987-2003. ( 22263297 )
2011
7
Superior vena cava syndrome in a man with situs inversus totalis and left main bronchus cancer. ( 19507488 )
2009
8
Stat bite: Mortality from lung and bronchus cancer by race/ethnicity, 1998-2002. ( 16449672 )
2006
9
Lung and bronchus cancer disparities in South Carolina: epidemiology and strategies for prevention. ( 17319229 )
2006
10
Stat bite: Incidence of lung and bronchus cancer by ethnicity, 1996-2000. ( 12902435 )
2003
11
Lung and bronchus cancer in women: a 21st-century epidemic. ( 12370622 )
2002
12
Association of esophageal achalasia and pulmonary actinomycosis infection simulating bronchial neoplasm. ( 10384207 )
1999
13
Papillary variant of low-grade mucoepidermoid carcinoma--an unusual bronchial neoplasm. A light microscopic, ultrastructural, and immunohistochemical study. ( 8135181 )
1994
14
The role of the fibreoptic bronchoscope in the diagnosis of bronchial neoplasm. ( 3688809 )
1987
15
Resection of bronchial neoplasm in the elderly. ( 3804680 )
1986
16
Bronchoscopy guided simulation of a bronchial neoplasm. ( 4030445 )
1985
17
Pulmonary actinomycosis simulating a bronchial neoplasm. ( 6875291 )
1983
18
Bronchial neoplasm with eosinophilia. ( 7306452 )
1981
19
Adenoid cystic carcinoma of the cervix presenting as a primary bronchial neoplasm. ( 4372888 )
1974
20
The bronchocele in bronchial neoplasm. ( 5417251 )
1970
21
Pemphigoid, bronchial neoplasm and radiotherapy. ( 6066575 )
1967
22
Bronchial neoplasm with endocrine, metabolic, and neurological manifestations. Report of a case. ( 4293855 )
1967
23
Cushing's syndrome associated with a "corticotrophin"-producing bronchial neoplasm neoplasm (results of corticotrophin assays and of pituitary-adrenal function tests). ( 4293813 )
1967
24
OPHTHALMOPLEGIA OF MYASTHENIA AND BRONCHIAL NEOPLASM. ( 14048792 )
1963
25
The role of radiation therapy in the treatment of primary bronchial neoplasm. ( 13600264 )
1958
26
BRONCHIAL neoplasm with myasthenia. ( 13118739 )
1954
27
Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine. ( 13110148 )
1953

Variations for Bronchus Cancer

Cosmic variations for Bronchus Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10660 TP53 lung,bronchus,carcinoma,NS c.818G>A p.R273H 16
2 COSM10718 TP53 lung,bronchus,carcinoma,NS c.524G>T p.R175L 16
3 COSM10662 TP53 lung,bronchus,carcinoma,NS c.743G>A p.R248Q 16
4 COSM10779 TP53 lung,bronchus,carcinoma,NS c.818G>T p.R273L 16
5 COSM10656 TP53 lung,bronchus,carcinoma,NS c.742C>T p.R248W 16
6 COSM6213 EGFR lung,bronchus,carcinoma,NS c.2582T>A p.L861Q 16

Expression for Bronchus Cancer

Search GEO for disease gene expression data for Bronchus Cancer.

Pathways for Bronchus Cancer

Pathways related to Bronchus Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.27 AVP AVPR2

GO Terms for Bronchus Cancer

Cellular components related to Bronchus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 clathrin-coated vesicle membrane GO:0030665 8.62 AVP AVPR2

Biological processes related to Bronchus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.33 AVP AVPR2 CRP
2 membrane organization GO:0061024 9.26 AVP AVPR2
3 acute-phase response GO:0006953 8.96 CRP SAA1
4 renal water homeostasis GO:0003091 8.62 AVP AVPR2

Sources for Bronchus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....